University of California Los Angeles (UCLA) - David Geffen School of Medicine
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huselton, Eric
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
Brake, Sami
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
MPCT-012L, NCT05826535: Study of IMPT-314 in R/R Aggressive B-cell NHL

Recruiting
1/2
150
US
IMPT-314
ImmPACT Bio
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/29
ELiPSE-1, NCT05336409: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Recruiting
1
75
US
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Century Therapeutics, Inc.
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
08/25
08/27
Pettito, Gabriella
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25

Download Options